Neuphoria Therapeutics Management
Management criteria checks 2/4
Neuphoria Therapeutics' CEO is Spyros Papapetropoulos, appointed in Jan 2023, has a tenure of 1.92 years. total yearly compensation is $905.47K, comprised of 61.3% salary and 38.7% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $39.78M. The average tenure of the management team and the board of directors is 1.4 years and 3.3 years respectively.
Key information
Spyros Papapetropoulos
Chief executive officer
US$905.5k
Total compensation
| CEO salary percentage | 61.3% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.4yrs |
| Board average tenure | 3.3yrs |
Recent management updates
No updates
Recent updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$11m |
| Jun 30 2024 | US$905k | US$555k | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$18m |
| Dec 31 2023 | n/a | n/a | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | US$616k | US$321k | -US$21m |
Compensation vs Market: Spyros's total compensation ($USD905.47K) is below average for companies of similar size in the US market ($USD12.84M).
Compensation vs Earnings: Spyros's compensation has increased whilst the company is unprofitable.
CEO
Spyros Papapetropoulos (51 yo)
1.9yrs
Tenure
US$905,469
Compensation
Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He served as Member of Scientific Advi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.9yrs | US$905.47k | 0.17% $ 39.8m | |
| Chief Financial Officer | 1.4yrs | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | US$237.80k | 0.0036% $ 845.9k | |
| Senior Vice President of Business Operations | 1.6yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Financial Controller | 1.4yrs | US$199.52k | 0% $ 0 | |
| Company Secretary | no data | no data | no data |
1.4yrs
Average Tenure
62yo
Average Age
Experienced Management: NEUP's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.9yrs | US$905.47k | 0.17% $ 39.8m | |
| Independent Non-Executive Director | 8.5yrs | US$38.06k | 0.0072% $ 1.7m | |
| Independent Non-Executive Chair of the Board | 8.3yrs | US$59.07k | 0.0029% $ 664.2k | |
| Independent Non-Executive Director | 4.2yrs | US$36.25k | 0% $ 0 | |
| Member of Clinical Advisory Board | 3.2yrs | US$43.30k | no data | |
| Member of Clinical Advisory Board | 3.2yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.4yrs | US$33.69k | 0.0077% $ 1.8m | |
| Member of Clinical Advisory Board | 3.2yrs | no data | no data |
3.3yrs
Average Tenure
57.5yo
Average Age
Experienced Board: NEUP's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:38 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Esther Lannie Hong | Berenberg |
| Charles Duncan | Cantor Fitzgerald & Co. |